-+ 0.00%
-+ 0.00%
-+ 0.00%

SSY Group wins China NMPA approval for Letermovir injection

PUBT·09/10/2026 05:09:39
Listen to the news
SSY Group wins China NMPA approval for Letermovir injection
  • SSY Group secured China NMPA production and registration clearance for Letermovir Injection (12ml:240mg), a type 4 chemical drug.
  • The product is used to prevent CMV infection in adult allogeneic hematopoietic stem cell transplant recipients.
  • The approval was dated Sept. 10, 2026, expanding the group’s perioperative injectable portfolio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260910-12327138), on September 10, 2026, and is solely responsible for the information contained therein.